The Study
Randomized Phase 2b Dose-Escalation Trial of Stem Cell Therapy with Laromestrocel for Aging Frailty
This study is like a fair test where some people got a new medicine and others got a fake one, and then researchers saw who walked farther. It shows the medicine probably helped people walk a bit farther, but it doesn't prove it fixes frailty for everyone or makes them younger.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists gave older adults with frailty a single IV drip of stem cells from young donors to see if it helps them walk better and feel less frail.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 588 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — walking 63 meters farther is more than the minimum amount doctors consider meaningful for frail older adults, meaning it likely helps them do daily tasks like walking around the block.
- 2At 9 months, those who got 200 million stem cells walked 63.4 meters farther than those who got a placebo — that's like walking an extra 1.5 football fields.
- 3Higher doses led to bigger improvements.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cell stem cell
Year
2026
Authors
J. G. Ruiz, A. Oliva, Kevin N. Ramdas, J. Javier, Jeffrey Rosen, Robert Perry, A. Blanco, Pedro Ylisastigui, Jeremy D. Walston, Hidenori Arai, E. Volpi, Anne B. Newman, Brittany Varnado, L. Mcclain-Moss, Eric Naioti, D. Mehranfard, D. Gincel, Chao Wang, M. Mintzer, Joel Danisi, G. Green, Jeffrey Botbyl, Zarin Zainul, Brian G. Rash, J. Hare
Related Content
Claims (10)
In adults aged 70 to 85 with mild-to-moderate frailty, a single intravenous infusion of 200 million allogeneic mesenchymal stem cells increases the distance walked in six minutes by 63.4 meters after nine months compared to a placebo.
People who walk farther in a six-minute walk test after receiving laromestrocel also report better physical function on a standardized questionnaire.
In adults aged 70 to 85 with mild-to-moderate frailty, a single intravenous infusion of 200 million bone marrow-derived stem cells increases the distance walked in six minutes by 63.4 meters after nine months compared to a placebo.
In older adults with frailty, receiving laromestrocel infusion does not lead to higher rates of serious adverse events, hospitalizations, falls, or death over nine months compared to receiving a placebo.
Laromestrocel stem cell therapy increases endurance and decreases frailty in older adults.
In older adults with frailty, receiving higher doses of laromestrocel between 25 million and 200 million cells leads to a consistent increase in how far they can walk in six minutes after nine months, with the highest dose showing a statistically greater improvement than placebo.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.